2019 journal article
Evaluation of the Tolerability of Combination Chemotherapy with Mitoxantrone and Dacarbazine in Dogs with Lymphoma
JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION, 55(2), 101–109.
MeSH headings : Animals; Antineoplastic Agents / administration & dosage; Antineoplastic Agents / adverse effects; Antineoplastic Agents / therapeutic use; Antineoplastic Combined Chemotherapy Protocols / therapeutic use; Dacarbazine / administration & dosage; Dacarbazine / adverse effects; Dacarbazine / therapeutic use; Dog Diseases / drug therapy; Dogs; Dose-Response Relationship, Drug; Female; Lymphoma / drug therapy; Lymphoma / veterinary; Male; Mitoxantrone / administration & dosage; Mitoxantrone / adverse effects; Mitoxantrone / therapeutic use; Neutropenia / chemically induced; Neutropenia / veterinary; Retrospective Studies
TL;DR:
The combination of mitoxantrone and DTIC is a safe treatment option for resistant lymphoma in dogs.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science; OpenAlex)
Source: Web Of Science
Added: March 4, 2019
ABSTRACT Combination chemotherapy can be an effective option for treating resistant lymphoma in dogs. This retrospective study examined the tolerability and efficacy of the combination of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (dacarbazine) (DTIC) in a population of dogs with lymphoma resistant to a doxorubicin-containing chemotherapy protocol. Mitoxantrone was administered at 5 mg/m 2 IV over 10 min followed by DTIC at 600 mg/m 2 IV over 5 hr, every 3 wk. All dogs were treated with prophylactic trimethoprim–sulfadiazine and metoclopramide. The frequency of grade 4 neutropenia was 18%, and 5% of dogs were hospitalized from sepsis. Gastrointestinal toxicity was uncommon. The overall response rate was 34% (15 of 44; 95% confidence interval 20–48%) for a median duration of 97 days (range 24–636 days, 95% confidence interval 44–150 days). Fourteen of 15 dogs who received mitoxantrone and DTIC as first rescue responded to treatment. Dogs who achieved complete remission to their initial L-asparaginase, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol were more likely to respond to mitoxantrone and DTIC (23 versus 11%, P = .035). The combination of mitoxantrone and DTIC is a safe treatment option for resistant lymphoma in dogs.